Business
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating
About this update from Indaptus Therapeutics, Inc.
[{"type":"text","content":"• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort • Single dose cohort data expected to be published at a scientific conference in 2024 NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces positive results from the second cohort of its Phase 1 INDP-D101 trial. Patients continue to exhibit a broad immune response similar to the first cohort. The preliminary results of this study were reviewed by the Company and an independent Safety Review Committee. Based on this review, it was recommended that the Company continue the trial and enroll patients for multiple doses of its lead therapeutic candidate, Decoy20. The company has immediately started screening potential patients. Jeffrey Meckler, Indaptus’ Chief Executive Officer, commented, “We have now confirmed the safety requirements necessary to advance our Phase 1 trial of Decoy20 to multi-dosing. The ability to do so is based on positive safety outcomes in the single dose regimen as well as the anti-cancer activity we observed from multi-dosing in our pre-clinical models.” The primary goal of the next stage of the trial is to determine the safety of Decoy20 when administered multiple times to the same patient, and to begin to examine the efficacy across multiple types of cancer. In animal models, Decoy20 was shown to be safe in several multiple dosing schedules. “The advancement to multi-dosing is our opportunity to potentially demonstrate what we saw in our preclinical models, namely, that multiple doses given consistently over time produce systemic immune responses that promote significant anti-tumor activity across multiple tumor types,” stated Dr. Michael Newman, Indaptus’ Founder and Chief Scientific Officer. Dr. Roger Waltzman, Indaptus’ Chief Medical Officer, added, \"While our Phase 1 trial is designed for safety and tolerability, it also provides our first opportunity to demonstrate the potential of our therapy in humans. We look forward to seeing how patients in this cohort tolerate and respond to Decoy20, which will also be instructive as we progress toward Phase 2.” About Indaptus Therapeutics In...